204 related articles for article (PubMed ID: 37792273)
1. Acthar
Kaplan J; Askanase A; Chu D; Abdellatif A; Basu D; Mirsaeidi M
Clin Drug Investig; 2023 Oct; 43(10):739-761. PubMed ID: 37792273
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
3. A Narrative Review of Acthar Gel for the Treatment of Myositis.
Chandra T; Aggarwal R
Rheumatol Ther; 2023 Jun; 10(3):523-537. PubMed ID: 36966453
[TBL] [Abstract][Full Text] [Related]
4. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
[TBL] [Abstract][Full Text] [Related]
5. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
Wan GJ; Niewoehner J; Hayes K
Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
[TBL] [Abstract][Full Text] [Related]
6. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
Askanase AD; Furie RA
Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications: A Scoping Review.
Tran KA; Harrod C; Bourdette DN; Cohen DM; Deodhar AA; Hartung DM
JAMA Intern Med; 2022 Feb; 182(2):206-217. PubMed ID: 34902005
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).
Gold LS; Suh K; Schepman PB; Damal K; Hansen RN
Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977
[TBL] [Abstract][Full Text] [Related]
11. Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.
Mirsaeidi M; Baughman RP
Pulm Ther; 2022 Mar; 8(1):43-55. PubMed ID: 35113366
[TBL] [Abstract][Full Text] [Related]
12. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
[TBL] [Abstract][Full Text] [Related]
13. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes.
Kutz C
Ther Adv Chronic Dis; 2016 Jul; 7(4):190-7. PubMed ID: 27433309
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.
Hayes K; Niewoehner J; Rice JB; Downes N; Hagopian E; Ma I; Wan GJ
Adv Ther; 2023 Nov; 40(11):4999-5015. PubMed ID: 37728695
[TBL] [Abstract][Full Text] [Related]
15. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection.
Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B
Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332
[TBL] [Abstract][Full Text] [Related]
16. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
Clinicoecon Outcomes Res; 2023; 15():739-752. PubMed ID: 37868649
[TBL] [Abstract][Full Text] [Related]
18. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
[TBL] [Abstract][Full Text] [Related]
19. ACTON PROLONGATUM® suppresses spasms head to head with Acthar® Gel in the model of infantile spasms.
Chern CR; Chern CJ; Velíšková J; Velíšek L
Epilepsy Behav; 2020 Apr; 105():106950. PubMed ID: 32092460
[TBL] [Abstract][Full Text] [Related]
20. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.
Li X; Golubovsky J; Hui-Yuen J; Shah U; Olech E; Lomeo R; Singh V; Busch H; Strandberg MJ; Strandberg K; Horowitz L; Askanase A
F1000Res; 2015; 4():1103. PubMed ID: 27158444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
